全文获取类型
收费全文 | 607篇 |
免费 | 44篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 71篇 |
妇产科学 | 8篇 |
基础医学 | 64篇 |
口腔科学 | 19篇 |
临床医学 | 77篇 |
内科学 | 126篇 |
皮肤病学 | 18篇 |
神经病学 | 77篇 |
特种医学 | 96篇 |
外科学 | 20篇 |
综合类 | 10篇 |
预防医学 | 16篇 |
眼科学 | 2篇 |
药学 | 31篇 |
中国医学 | 1篇 |
肿瘤学 | 15篇 |
出版年
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 2篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 10篇 |
2016年 | 8篇 |
2015年 | 17篇 |
2014年 | 12篇 |
2013年 | 28篇 |
2012年 | 13篇 |
2011年 | 12篇 |
2010年 | 31篇 |
2009年 | 20篇 |
2008年 | 18篇 |
2007年 | 13篇 |
2006年 | 16篇 |
2005年 | 11篇 |
2004年 | 7篇 |
2003年 | 4篇 |
2002年 | 11篇 |
2001年 | 13篇 |
2000年 | 4篇 |
1999年 | 14篇 |
1998年 | 25篇 |
1997年 | 33篇 |
1996年 | 28篇 |
1995年 | 32篇 |
1994年 | 23篇 |
1993年 | 37篇 |
1992年 | 9篇 |
1991年 | 8篇 |
1990年 | 18篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 12篇 |
1986年 | 14篇 |
1985年 | 17篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 15篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1976年 | 14篇 |
1975年 | 5篇 |
1971年 | 2篇 |
1968年 | 3篇 |
排序方式: 共有652条查询结果,搜索用时 78 毫秒
61.
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy 总被引:3,自引:0,他引:3
Pålhagen S Canger R Henriksen O van Parys JA Rivière ME Karolchyk MA 《Epilepsy research》2001,43(2):115-124
OBJECTIVE: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy in epileptic patients. The pharmacokinetic (PK) profile of rufinamide was also determined. METHODS: Fifty patients with diagnoses of partial or primary generalized tonic-clonic seizures were enrolled in this 28-day double-blind, placebo-controlled, weekly rising dose (400-1600 mg/day) trial. PK profiles were obtained after administration of single-dose rufinamide prior to and after the Double-blind phase. RESULTS: In the evaluable patient population, seizure frequency decreased by 41% in the rufinamide group and increased by 52% in the placebo group (P=0.040). Thirty-nine percent (39%) of rufinamide-treated and 16% of placebo-treated patients experienced reduction in seizure frequency of at least 50% relative to baseline (P=0.096). SAFETY: Treatment-emergent adverse events (AEs) consisted mainly of neurologic signs and symptoms commonly associated with antiepileptic drugs (AEDs). PHARMACOKINETICS: At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h. No autoinduction of rufinamide metabolism occurred. Rufinamide did not influence the plasma concentration of carbamazepine, phenytoin or valproate when added to these single AED regimens. CONCLUSION: Rufinamide has been shown, in this proof of principle trial, to be safe and effective in reducing seizure frequency in epileptic patients with no relevant influence on the metabolism of other AEDs. 相似文献
62.
PURPOSE: The aim of the present study was to investigate the possible frontal cognitive dysfunction in patients with juvenile myoclonic epilepsy (JME) and to compare the results with those of patients with frontal lobe epilepsy (FLE) and temporal lobe epilepsy (TLE), as well as with controls. METHODS: A total of 50 patients with JME, 40 patients with FLE, 40 patients with TLE, and 40 normal controls, all matched for age, education, and IQ, were administered tests to assess frontal functions (the Word Fluency Test and the Wisconsin Card Sorting Test [WCST]). All participants had a normal intelligence level based on the Wechsler Adult Intelligence Scale, and did not take medications other than antiepileptics (AEDs) or have a psychiatric history. RESULTS: Patients with JME had severe impairment in all administered tasks, similar to that of patients with FLE; TLE patients and controls followed in order. Multiple regression analysis did not disclose any significant effect of clinical variables on the cognitive deficits. DISCUSSION: These results clearly suggest that JME patients can show some frontal dysfunction, which may affect both epileptogenic features and cognitive processes. Further studies are needed to confirm these findings. 相似文献
63.
Uncoordinated expression of fibrinogen compared with thrombospondin and von Willebrand factor in maturing human megakaryocytes 总被引:7,自引:1,他引:7
Cramer EM; Debili N; Martin JF; Gladwin AM; Breton-Gorius J; Harrison P; Savidge GF; Vainchenker W 《Blood》1989,73(5):1123-1129
The localization of three known alpha-granule proteins, thrombospondin (TSP), von Willebrand factor (vWF), and fibrinogen (Fg) has been studied in human megakaryocytes (MK) by immunofluorescence and immunoelectron microscopy. For this study, highly purified populations of MK were prepared from human bone marrow either by counterflow centrifugal elutriation or by cell culture from normal subjects and from two patients with megakaryoblastic leukemia. In normal bone marrow immature MK, TSP, and vWF were observed in the Golgi-associated vesicles and in small immature alpha-granules; in mature MK, they were found in the matrix of the mature large alpha-granules. Surprisingly, Fg was detected neither in the Golgi area, nor in the small precursors of alpha-granules; it was only found in the mature alpha-granules but this labeling was generally weaker than in blood platelets. In order to confirm these differences between the expression of Fg and vWF or TSP additional studies were performed on cultured maturing MK: immunofluorescent and ultrastructural immunogold labeling confirmed that vWF appeared early in the maturation while the same immature MK were negative for Fg. In the late maturation stage, the three proteins were detected in the alpha-granules. In order to know whether Fg was lately synthesized or endocytosed from the outside medium, normal MK were grown in the presence of either normal or afibrinogenemic plasma, and normal serum. Fg was detected only in the alpha-granules of MK grown in normal plasma. Similar results were observed with malignant MK, whose maturation was independent of the culture conditions. In conclusion, this study brings immunocytochemical evidence that vWF and TSP are synthesized by immature MK, whereas Fg appears later in the MK alpha-granules and its expression is dependent of the presence of an exogenous Fg source. 相似文献
64.
65.
Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor population 总被引:5,自引:17,他引:5
Long-term culture-initiating cells (LTC-IC) are hematopoietic progenitors able to generate colony-forming unit-cells (CFU) after 5 to 8 weeks (35 to 60 days) of culture on bone marrow (BM) stroma and represent the most primitive progenitors currently detectable in vitro. We have recently reported that long-term cultures initiated with CD34+CD38- cells from BM or cord blood are able to continue generating CFU for at least 100 days, ie, beyond the standard LTC-IC period. In this report, single-cell cultures from cord blood and retroviral marking of cord blood and BM were used to study whether the subpopulation of CD34+CD38- cells able to generate CFU beyond 60 days ("extended long-term culture-initiating cells" or ELTC-IC) are functionally distinct from LTC-IC in terms of timing of initial clonal proliferation and generative capacity. All cord blood LTC-IC formed clones of greater than 50 cells by day 30. In contrast, cord blood ELTC- IC proliferated later in culture, 50% forming clones after day 30. Although efficient retroviral marking of LTC-IC was seen (25% to 45%), marking of ELTC-IC was inefficient (< 1%), consistent with a more quiescent progenitor population. There was a positive correlation between time of clonal proliferation and generative capacity. ELTC-IC generated threefold to fourfold more progeny than did LTC-IC (P < .002). These studies show that there is a functional hierarchy of progenitors in long-term culture which correlates with their level of quiescence. By extending the LTC-IC assay, a more primitive progenitor may be studied that may be functionally closer to the human long-term repopulation stem cell in vivo. 相似文献
66.
Francis L. Counselman MD Chair Marc A. Borenstein MD Carey D. Chisholm MD Michael L. Epter DO Sorabh Khandelwal MD Chadd K. Kraus DO MPH Samuel D. Luber MD MPH Catherine A. Marco MD Susan B. Promes MD Gillian Schmitz MD for the EM Model Review Task Force Julia N. Keehbauch for the American Board of Emergency Medicine 《Academic emergency medicine》2014,21(5):574-598
In 2001, “The Model of the Clinical Practice of Emergency Medicine” was first published. This document, the first of its kind, was the result of an extensive practice analysis of emergency department (ED) visits and several expert panels, overseen by representatives from six collaborating professional organizations (the American Board of Emergency Medicine, the American College of Emergency Physicians, the Society for Academic Emergency Medicine, the Residency Review Committee for Emergency Medicine, the Council of Emergency Medicine Residency Directors, and the Emergency Medicine Residents' Association). Every 2 years, the document is reviewed by these organizations to identify practice changes, incorporate new evidence, and identify perceived deficiencies. For this revision, a seventh organization was included, the American Academy of Emergency Medicine. 相似文献
67.
al-Shahi R; Mason JC; Rao R; Hurd C; Thompson EM; Haskard DO; Davies KA 《Rheumatology (Oxford, England)》1997,36(7):794-798
Thrombocytopenia in patients with acute systemic lupus erythematosus (SLE)
frequently presents the clinician with considerable diagnostic and
therapeutic difficulties. In this Grand Round, we present a 48-yr- old
woman with a 7 yr history of lupus, who presented with acute proliferative
glomerulonephritis and nephrotic syndrome, pneumonia, profound
hypocomplementaemia and a severe microangiopathic haemolytic anaemia with
associated thrombocytopenia. Her thrombocytopenia proved initially
refractory to conventional immunosuppressive therapy, and corticosteroids,
and resolved only with plasma exchange and repeated fresh frozen plasma
infusions. Serological testing revealed high-titre antinuclear antibodies
(ANA) and markedly raised antibodies to double- stranded (ds) DNA, but no
significant elevation in anticardiolipin antibodies. Platelet-associated
IgG and IgM and antibodies to the CD36 glycoprotein antigen, expressed on
platelets and endothelium, were detected in the serum. We address some of
the difficult diagnostic and management issues raised by this complex
patient and the possible immunopathological links between antibodies to
CD36, immune-mediated red cell destruction, thrombocytopenia and thrombotic
microangiopathic haemolytic anaemia.
相似文献
68.
Using albumin and crystalloid as the only replacement fluids, the effect of partial plasma exchange on the removal and recovery of normal plasma constituents was studied. The results of 30 procedures on 10 individuals were evaluated. Four patterns of removal are described: reduction in the concentration of fibrinogen and C3 were greater than would be expected based upon the extent of the exchange, while IgG, IgM, cholesterol, alkaline phosphatase and SGPT were removed as expected. Reduction of serum glutamicoxalacetic transaminase (SGOT), lactate dehydrogenase (LDH), amylase, and creatine phosphokinase (CPK) averaged 17% less, and uric acid, calcium and K+ averaged 53% less than expected. Concentrations of HCO-3 and glucose did not change. The mean recovery for all constituents except fibrinogen, C3, cholesterol. IgG and IgM was near 100% at 48-72 hr postpheresis. The 72-hr recovery of fibrinogen and complement was 66% and 60%, respectively. Cholesterol recovery was also slow, requiring a minimum of 1 wk to reach prepheresis levels. Measured at a time when quantitative IgM levels were still reduced, alloantibody agglutinating activity (anti-A and anti-B) in a postpheresis sample exceeded prepheresis agglutinating activity. These data demonstrated that, depending upon quantity and frequency of pheresis, partial plasma exchange using albumin replacement may cause progressive marked reduction in concentrations of immunoglobulin, complement, fibrinogen, and cholesterol. Furthermore, newly synthesized antibody may have increased biologic activity. 相似文献
69.
Treatment of two patients with B cell lymphoma with monoclonal anti- idiotype antibodies 总被引:2,自引:0,他引:2
Mouse monoclonal anti-idiotype antibodies have been used to treat two patients with progressive advanced B cell non-Hodgkin's lymphoma. Transient falls in the level of circulating malignant cells and idiotypic immunoglobulin were produced, and free unbound monoclonal antibody was identified in the serum. Homing of the antibodies to tumor cells in the blood, bone marrow, ascites, and lymph nodes was demonstrated in both patients. Although large amounts of anti-idiotype antibody were given (3.8 g and 5.8 g), no toxic effects were seen, and no antibodies to the foreign mouse protein were made. There was no modulation of the antigen from the tumor cells and no indication of immunoselection. There was evidence of large-scale tumor cell destruction, but only a modest reduction in tumor size. The killing of the tumor cells was mediated by the reticuloendothelial system and not by complement. 相似文献
70.
Four of five infants and young children with acute monoblastic leukemia, a disease that heretofore has been highly refractory to therapy, were successfully treated with sequential infusions of a podophyllin derivative employed as a single agent over a protracted period of time. In three of the five children, monocytic leukemia cutis was present at birth. Treatment was begun in two of them when the disease had progressed to systemic involvement at a few months of age, and in the third when disease was still localized. The other two children were 11 and 18 months of age at initial presentation with widespread disease. Four children are off therapy 11 months, 26 months, 5 years, and 6 years, respectively. 相似文献